Book demo
> Trellis Blog <
Articles & insights to keep you updated on our latest developments
Articles & insights to keep you updated on our latest developments
Stay up-to-date with our latest platform developments.
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Navigating Eylea (Aflibercept) Prior Authorization Policies Across Major U.S. Payers
Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Eylea (aflibercept) is a leading anti-VEGF (vascular endothelial growth factor) therapy indicated for retinal conditions such as neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Read more
Recent Posts
All Posts
Prior Auth
Specialty
Specialty
Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now
Jul 11, 2025
Prior Auth
Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order
Jul 11, 2025
Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend
Jul 11, 2025
Specialty
Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
Jul 10, 2025
Prior Auth
The Dirty Seven: 7 Prior-Authorization Denial Codes Costing Infusion Centers the Most
Jul 10, 2025
Specialty
Prepare for 4% Medicare Cuts: 5 Steps Clinics Must Take
Jul 10, 2025
Specialty
Medicare Part B Margins Decreasing Under New Bill
Jul 7, 2025
Specialty
How the Big Beautiful Bill Impacts Infusion Clinic Margins
Jul 3, 2025
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Jun 26, 2025
Load More
Recent Posts
All Posts
Prior Auth
Specialty
Specialty
Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now
Jul 11, 2025
Prior Auth
Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order
Jul 11, 2025
Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend
Jul 11, 2025
Specialty
Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
Jul 10, 2025
Prior Auth
The Dirty Seven: 7 Prior-Authorization Denial Codes Costing Infusion Centers the Most
Jul 10, 2025
Specialty
Prepare for 4% Medicare Cuts: 5 Steps Clinics Must Take
Jul 10, 2025
Specialty
Medicare Part B Margins Decreasing Under New Bill
Jul 7, 2025
Specialty
How the Big Beautiful Bill Impacts Infusion Clinic Margins
Jul 3, 2025
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Jun 26, 2025
Load More
Recent Posts
All Posts
Prior Auth
Specialty
Specialty
Medicare Part B Drug-Pricing Reforms Coming in 2026—What Providers Should Do Now
Jul 11, 2025
Prior Auth
Navigating 340B, Site-Neutral & Prior-Auth Rules After the 2025 Executive Order
Jul 11, 2025
Biosimilars in 2025: Adoption Strategies That Save Infusion Centers 20 % on Drug Spend
Jul 11, 2025
Specialty
Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
Jul 10, 2025
Prior Auth
The Dirty Seven: 7 Prior-Authorization Denial Codes Costing Infusion Centers the Most
Jul 10, 2025
Specialty
Prepare for 4% Medicare Cuts: 5 Steps Clinics Must Take
Jul 10, 2025
Specialty
Medicare Part B Margins Decreasing Under New Bill
Jul 7, 2025
Specialty
How the Big Beautiful Bill Impacts Infusion Clinic Margins
Jul 3, 2025
Prior Auth
Keytruda (Pembrolizumab): Prior Authorization Guidelines and Utilization Overview Across Major U.S. Payers
Jun 26, 2025
Load More
> Start today <
Let us take care of the MESS(y) data
Let us take care of the MESS(y) data
Click below to get access to our product and explore how Trellis can help you and your organization unlock new insights!
Book demo
Book demo
Book demo
2025 Trellis. All rights reserved.
2025 Trellis
2025 Trellis. All rights reserved.